Drug Trial Radar · NCT06736262
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
67
Actual
Start
Nov 26, 2024
Primary completion
Jul 21, 2026
Study completion Jul 21, 2026
Sponsor
- Lead sponsor
- Jasper Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
Conditions
- Urticaria Chronic
Interventions
BriquilimabDrug
No additional details needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of briquilimabTime frame: From signing the informed consent form through study completion (an average of one year)
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Investigative Site 118
Birmingham, Alabama
Investigative Site 108
Little Rock, Arkansas
Investigative Site 105
San Diego, California
Investigative Site 116
Tampa, Florida
Investigative Site 109
Boise, Idaho
Investigative Site 124
Normal, Illinois
Investigative Site 110
Indianapolis, Indiana
Investigative Site 123
Lafayette, Louisiana
Investigative Site 101
Baltimore, Maryland
Investigative Site 121
White Marsh, Maryland
Investigative Site 103
Cincinnati, Ohio
Investigative Site 111
Murray, Utah
Investigative Site 115
Seattle, Washington
Investigative Site 201
Berlin, Germany
Investigative Site 210
München, Bavaria, Germany
Investigative Site 202
Marburg, Hesse, Germany
Investigative Site 204
Münster, North Rhine-Westphalia, Germany
Investigative Site 209
Dresden, Saxony, Germany
Investigative Site 206
Lübeck, Schleswig-Holstein, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.